Q1 2026 Recap: Cardiology News and Updates

Despite being a relatively quiet first quarter in terms of approvals from the US Food and Drug Administration (FDA), cardiology had no shortage of groundbreaking developments over the first 3 months of 2026. Between major trial results and substantial overhauling of guidelines, everything from heart failure and cardiomyopathy to dyslipidemia and myocardial infarction saw significant advancements. Additionally, the American College of Cardiology (ACC) Scientific Sessions 2026, conducted in New Orleans, Louisiana, from March 28-30, brought with it a tremendous amount of news across a plethora of specialties.